Conference Reports for NATAP

Back

Select Key IAC 2018 Highlight Reports / Coverage: ART drugs, PrEP, Aging/Comorbidities/Mortality/Fatty Liver/Heart & Kidney diseases       New Updated IAC Reporting, Prevention Report coming   IAC: Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a crosssectional analysis - (08/08/18)   IAC: Antiretroviral Treatment Maintenance Strategies and Blood Telomere Length Change (08/08/18)   IAC: Weight Gain After ARV Initiation Correlates with Increased Inflammatory Biomarkers (08/08/18)   IAC: Severe menopausal symptoms double odds of poor ART adherence in UK women - (08/08/18)   IAC: CD4 count and viral load tied to atherogenic cholesterol in people with HIV - (08/07/18)   IAC: Vitamin D does not modulate immune-mediated bone loss during ART initiation: A5280 - (08/07/18)   IAC - High incidence of HCV (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment - (08/07/18)   IAC: Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - (08/06/18)   IAC: Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris - (08/06/18)   IAC: Statins not linked to lower HIV persistence, inflammation, or immune activation - (08/06/18)   IAC: High uptake of yearly digital rectal exam for anal cancer in Australian MSM with HIV - (08/06/18)     Key Selected IAC Reports   103 posted here is link IAC 2018 - 22nd International AIDS Conference Amsterdam, The Netherlands July 22-27   Leading Studies: * No HIV Sex Transmission Found- * PARTNER2 Study; * On Demand PrEP; * HEART Study - Heart Disease in HIV+ a Concern: 50% higher rates of heart failure; * 2-Drug Therapy GEMINI Study - Dolutegravir+3TC; * Doravirine New NNRTI; * 2 Years Dolutegravir+Rilpivirine - 2 Drug Regimen; * Darunavir-C/F/TAF Switched to & Rapid 'Test & Treat ART within SF; * Neural tube defects with dolutegravir   IAC: HIV transmission risk through condomless sex in gay couples with suppressive ART: The PARTNER2 Study extended results in gay men - (07/25/18)   IAC: the PARTNER Study: new results from PARTNER 2 - PDF - Q and A - (07/25/18)   IAC: PARTNER-2 Study No HIV transmissions in 8 years when gay HIV+ partner has undetectable load - Mark Mascolini (07/25/18)   IAC: Incidence of HIV-infection in the ANRS Prevenir Study in the Paris Region with Daily or On Demand PrEP with TDF/FTC - (07/26/18)   IAC: HIV infection independently increases the risk of developing heart failure: The HIV HEART study   IAC: Beyond the 60s: Changing co-morbidities in people living with HIV aged over 60 attending clinic in 2010 and 2017 - (07/25/18)   IAC: Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - (08/06/18)     ART - HIV Therapy   IAC: Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)   IAC: Surveillance for Neural Tube Defects following Antiretroviral Exposure from Conception - (07/30/18)   IAC: DolPHIN-1: Randomised controlled trial of dolutegravir(DTG)-versus efavirenz(EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy - (07/26/18)   IAC: Doravirine (DOR) Versus Ritonavir-Boosted Darunavir (DRV+r): 96-Week Results of the Randomized, Double-Blind, Phase 3 DRIVE-FORWARD Noninferiority Trial - (07/25/18)   IAC: Characterization of Doravirine-Selected Resistance Patterns From Participants in Treatment-Naïve Phase 3 Clinical Trials - (07/30/18)   IAC: Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591 - (07/30/18)   IAC: Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen (07/27/18)   IAC: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in a Test-and-Treat Model of Care for HIV-1 Infection: Interim Analysis of the DIAMOND Study - (07/26/18)   IAC: Durable Suppression 2 Years After Switch to DTG + RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies(07/27/18)   IAC: Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/r) plus 2 NRTIs in second-line treatment - 48-week data from the DAWNING Study - (07/27/18)   IAC: Patient Satisfaction, Tolerability and Acceptability of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting Therapy in HIV-1-Infected Adults: LATTE-2 Week 96 Results (07/27/18)   IAC: INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV CO-INFECTED ADULTS AT WEEK 48 - (07/26/18)   IAC: A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824): Week 24 Results (08/06/18)   IAC: Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 24 Subgroup Analysis in Randomized Cohort Participants (07/27/18)   IAC: Adherence to Long-Acting CAB and RPV Injections Through 96 Weeks of Maintenance Therapy in LATTE-2 / Good adherence to injected cabotegravir and rilpivirine in 230 LATTE-2 participants - (07/31/18)     PrEP   IAC: Incidence of HIV-infection in the ANRS Prevenir Study in the Paris Region with Daily or On Demand PrEP with TDF/FTC - (07/26/18)   IAC: The Impact of Pre-exposure Prophylaxis With FTC/TDF on HIV Diagnoses, 2012-2016, United States - (07/25/18)   IAC: PrEP use rising in US MSM, but rectal STI rate remains stable - (08/01/18)   IAC: Among 2590 US adolescents using PrEP, 83.5% are girls, 59% on Medicaid - (07/27/18)   IAC: The Impact of Pre-exposure Prophylaxis with FTC/TDF on HIV Diagnoses, 2012-2016, United States (07/27/18)   IAC: Changes, Patterns and Predictors of Sexually Transmitted Infections in Gay and Bisexual Men Using PrEP - Interim Analysis from the PrEPX Study - (08/01/18)   IAC: Healthcare Utilization and STI Incidence in Young Men on Pre-exposure Prophylaxis (PrEP) Compared to Young Men Who Are Not on PrEP: The PrEPARE Study - (08/01/18)   Aging / Comorbidities / Fatty Liver / Kidney & Heart Diseases / Mortality in HIV+ Women & Men       NEW - IAC Reports   IAC: Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a crosssectional analysis - (08/08/18)   NEW IAC - IAC: Antiretroviral Treatment Maintenance Strategies and Blood Telomere Length Change - (08/08/18) NEW IAC - IAC: Weight Gain After ARV Initiation Correlates with Increased Inflammatory Biomarkers - (08/08/18)   NEW IAC - IAC: CD4 count and viral load tied to atherogenic cholesterol in people with HIV - Mark Mascolini (08/07/18)   NEW IAC: Vitamin D does not modulate immune-mediated bone loss during ART initiation: A5280 (08/07/18)   IAC: Beyond the 60s: Changing co-morbidities in people living with HIV aged over 60 attending clinic in 2010 and 2017 - (07/25/18)   IAC: HIV infection independently increases the risk of developing heart failure: The HIV HEART study - (07/30/18)   IAC: Kaposi sarcoma incidence flat among black men in southern US (07/27/18)   IAC: Antiretroviral therapy (ART) interruption is associated with reduced cortical structures at age 5 years compared to uninterrupted. - (07/25/18)   IAC: A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated With Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database - Liver Chemistry Elevations/DILI (08/01/18)   IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study -(07/31/18)   IAC: Trends in mortality among HIV-infected subjects; differences by HCV coinfection - 70% of Deaths Non-AIDS: liver-HCV, psychiatric, malignancies, cardiovascular & pulmonary diseases common causes of death (07/31/18)   IAC: "Increased risk of both mortality and incident comorbidity among frail HIV-positive and HIV-negative participants and increased risk of frailty progression in those with HIV." (07/31/18)   IAC: Mortality after ART starts remains higher in women in Americas and Africa than in Europe - - (07/25/18)   IAC: Mortality 4.5 times higher in Canadian women with HIV than in general population - (07/27/18)   IAC: Mortality and cause of death among HIV patients in London in 2016: 77% Die of Non-AIDS Conditions/Comorbidities/majority virally suppressed - Ending AIDS? Only applies to stopping new transmissions? -(07/27/18)   IAC: Comparison of depression and anxiety between HIV-positive and HIV-negative people.... 3-7 Times Higher Rates for HIV+/Aging Increases Rates (08/02/18)   IAC: Half of adults in HIV group have insomnia--fewer than half of them treated (08/02/18)   IAC: Noncommunicable disease rates with HIV lower in England than in 4 other countries - (07/31/18)   IAC: Possible link between HIV and vestibular impairment in men and women - (08/03/18)   ------------------------     Others   IAC: HIV DNA reservoir size and make-up "remarkably" stable through 20 years of ART - Mark Mascolini (08/03/18)   IAC: HIV incidence drops in Melbourne MSM, reflecting changing HIV testing and control - Mark Mascolini (08/06/18)   IAC: COMPLACENCY IS THE NEW PROBLEM: COMPARATIVE ANALYSIS OF RECENT OUTBREAKS OF HIV AMONG PERSONS WHO INJECT DRUGS IN EUROPE AND NORTH AMERICA (08/06/18)   IAC: Partner Violence: A Significant Part of a Syndemic Among Black Men Who Have Sex With Men (08/06/18)   IAC: Kick-and-kill with vaccines plus vorinostat has no impact on CD4 reservoir - (07/24/18)